TerminatedPhase 1NCT02924038

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Studying Glial tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nicholas Butowski
Principal Investigator
Hideho Okada, MD, PhD
University of California, San Francisco
Intervention
IMA950(biological)
Enrollment
14 enrolled
Eligibility
18 years · All sexes
Timeline
20172022

Study locations (1)

Collaborators

Celldex Therapeutics · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02924038 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor

← Back to all trials